Click here to access full coverage of Minter Ellison in The Lawyer Asia Pacific 150 2014. The report is an essential business intelligence resource for anyone interested in Asia-Pacific's growing legal services market.
While many of its peers in Australia have chosen to tie up with an international firm, Minter Ellison has moved forward its agenda to be an Asia-Pacific regional player in its own right.
In 2012, the Australian firm opened an office in Mongolia to capitalise on the country's emerging resource-based economy. Hong Kong partner Elisabeth Ellis has relocated to Ulaanbaatar to become the office’s resident partner. She is supported by a team of local lawyers, as well as the firm's regional energy and resource team.
The expansion is in line with the firm's strategic focus on the energy and resources industry, and will create natural synergy with its existing Asian offices in Beijing, Shanghai and Hong Kong.
Elsewhere in Asia, the firm has a nine-partner Greater China team across Hong Kong, Beijing and Shanghai. A presence in North Asia is important to the firm, because to build up a credible energy and resources practice in Australia, the firm needs to be close to North Asia clients.
Having recognised the busy deal flow between Perth and Asia, the firm has also put in efforts on rebuilding its Perth office, where a large team led by 18 partners walked out to set up an office for US firm Squire Sanders in August 2011. The Perth departures were triggered by Minters' move to fully financially integrate the Perth office with its East Coast offices, including Sydney, Melbourne and Brisbane.
News from Minter Ellison
News from The Lawyer
Briefings from Minter Ellison
Asia Region Funds Passport: draft rules a step towards a regional market for managed investment funds
The Asia Region Funds Passport will create a regional market for managed investment funds and give Australian fund managers an opportunity to increase their presence in Asia.
The Federal Court of Australia has dismissed the ACCC’s anti-competitive conduct case against Pfizer, finding that Pfizer did not breach the prohibition on misuse of market power.